Michael Nevradakis

Moderna raked in signi cant earnings in 2022, based on $18.4 billion in sales of its mRNA COVID-19 vaccine — the company’s one and only product on the market.

But in a Jan. 9 update on the company’s “industry-leading mRNA pipeline,” Moderna told investors it is developing multiple new mRNA products — including a treatment designed to be injected directly into the hearts of patients who have sustained heart attacks or heart failure.

Moderna said it launched a phase 1B clinical trial of its mRNA-0184 injection, which it said: “encodes for relaxin, a naturally occurring hormone that is known to cause hemodynamic changes that are potentially bene cial for heart failure patients.”